Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

A Study on the Inhibitory Effect of Yeongdamsagantang onAlzheimer in Aβ-oligomer-induced Neuro 2A Cell Lines

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2008, v.29 no.2, pp.151-164






  • Downloaded
  • Viewed

Abstract

Objective: To investigate the effects of Yeongdamsagantang (YDGT) on apoptosis of neuronal cells that can result in dementia. Method: The water extract of the YDGT was tested in vitro for its beneficial effects on neuronal survival and neuroprotective functions, particularly in connection with Aβ oligomer-related dementias. Aβ oligomers derived from proteolytic processing of the β-amyloid precursor protein (APP), including the amyloid-β peptide (Aβ), play a critical role in the pathogenesis of Alzheimer's disease. A neuroblastoma cell line stably expressing an Aβ oligomer- associated neuronal degeneration was used to investigate if YDGT inhibits formation of Aβ oligomer. To measure the ATP generating level in mitochondrial membrane, luciferin/luciferase luminescence kit (Promega) and luminator was used, and to survey the protein's apparition, confocal microscopy was used. Result: Aβoligomer had a profound attenuation in the increase in CT105 expressing neuro2A cells from YDGT. Experimental evidence indicates that YDGT protected against neuronal damage from cells, but its cellular and molecular mechanisms remain unknown. We demonstrated that YDGT inhibited formation of amyloid-β (Aβ) oligomers, which were the behavior, and possibly causative, features of AD. The decreased Aβ oligomer in the presence of YDGT was observed in the conditioned medium of this Aβoligomer-secreting cell line under in vitro. In the cells, YDGT significantly attenuated mitochondrion-initiated apoptosis. Conclusion: (i) a direct Aβ oligomer toxicity and the apoptosis initiated by the mitochondria; and (ii) multiple cellular and molecular neuroprotective mechanisms, including attenuation of apoptosis and direct inhibition of Aβ oligomer aggregation, underlie the neuroprotective effects of YDGT.

keywords
Yeongdamsagantang (YDGT), inhibition of Aβ oligomer aggregation, Alzheimer


Reference

1

1. 배영철. 노인의학. 서울; 고려의학: 1996:193-209,

2

2. 大友英一 : 老年期痴呆の對應, 日本; 永井書店; 1993:1.

3

3. Brosnan, C. F., Selmaj, F. K. and Raine, C. S. Hypothesis: a role for tumor necrosis factor in immune-related demyelination and its relevance to multiple sclerosis. J. Neuroimm- unol. 1998: 18, 87.

4

4. Fillit, H., Ding, W. H., Buce, L. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neuroscience Lett. 1991 129, 318D.

5

5. 이근후 : 최신임상정신의학. 서울; 하나의학사; 1988:138, 216-28.

6

6. Hyeon-jin Kim, Soo-cheon Chae, Daekwon- Lee. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEBJ. 2003(17):118-120.

7

7. 이봉교. 症狀鑑別治療. 서울: 성보사; 1991:122-6.

8

8. 陳士澤. 國譯石室秘錄. 서울: 書苑堂; 1984:102, 316, 317.

9

9. 錢鏡湖. 辨證奇問全書. 台北: 甘地出版社; 1990: 222-5, 233-5.

10

10. 孫思邈. 備急千金要方. 서울: 杏林出版社; 1982: 129-35, 534, 545, 550.

11

11. 李東垣 외. 東垣十種醫書. 서울: 대성문화사; 1983:219-220.

12

12. 손성향. Combined Treatment of Colchicine and Herbal Medicines (Gamichunghyulbohyul- tang of Gamiyongdamsagan-tang) Attenuate the Behcet's Disease Symptoms in Mice. 大韓韓醫學會誌. 2001;22(2):102-108.

13

13. 金南權. 龍膽瀉肝湯의 抗바이러스 活性 및 免疫反應에 對한 實驗的 考察. 大韓外官科學會誌 1998(11):1-22.

14

14. 김창환, 김경준. 龍膽瀉肝湯加減方의 止血效果에 關한 實驗的 硏究. 大韓眼耳鼻咽喉皮膚科學會誌 2002:15(1):63-75.

15

15. 최은규, 노석선. 용담사간탕가미방이 염증치료 및 예방에 미치는 영향에 대한 연구. 大韓眼耳鼻咽喉皮膚科學會誌. 2004;17(2):39-47.

16

16. 김의태, 안규석. 용담사간탕 및 조구등, 하고초, 차전자 가미방이 고혈압에 미치는 영향. 동의병리학회지. 1990(5);15-23.

17

17. Jae Chang Lee, Sok Cheon Pak, Seung Hoo Lee. The Effect of Herbal Medicine on Nerve Growth Factor in Estradiol Valerate-induced Polycycstic Ovaries in Rats. The American Journal of Chinese Medicine. 2003;31(6):885 -895.

18

18. E. H. Lee, N. K. Kim, C. Y. Hwang. Activation of inducible nitric oxide synthase by Yongda-Sagan-Tang in mouse peritoneal macrophages. Journal of Ethnopharmacologoy. 1998(60):61-69.

19

19. 黃道淵 : 方藥合篇, 서울:南山堂;1978:178, 205.

20

20. Selmaj, K. W. Raine, C. S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 1998(23):339.

21

21. Nilsberth C, Westlind-Danielsson A, Eckman CB. The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001 Sep; 4(9):887-93.

22

22. Wiltfang J, Esselmann H, Cupers P. Elevation of Abeta peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem. 2001(Aug): 28

23

23. Riddell DR, Christie G, Hussain I. Compart- mentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol. 2001 Aug 21;11(16):1288-93.

24

24. Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science. 2001 Aug 24;293(5534):1449-54.

25

25. Bhojak TJ, DeKosky ST, Ganguli M. Genetic polymorphism in the cathepsin G gene and the risk of Alzheimer's disease. Neurosci Lett. 2001 Aug 24;309(2):138-40.(385)

26

26. De Jonghe C, Esselens C, Kumar-Singh S. Pathogenic APP mutations near the gamma- secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001 Aug 1;10 (16):1665-71.

27

27. Iwatsubo T. Beta-amyloid cascade: current status and future directions. Rinsho Shinkeigaku. 2000 Dec;40(12):1228-30.

28

28. Neve RL, McPhie DL, Chen Y. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? Biochem Soc Symp. 2001 (67):37-50

29

29. Dewachter I, Moechars D, van Dorpe J, Tesseur I. Modelling Alzheimer's disease in multiple transgenic mice. Biochem Soc Symp. 2001(67):203-10.

30

30. Hoozemans JJ, Rozemuller AJ, Veerhuis R, Eikelenboom P.Immunological aspects of alzheimer's disease: therapeutic implications. BioDrugs. 2001 15(5):325-37.

31

31. Nowotny P, Kwon JM, Chakraverty S. Association studies using novel polymorphisms in BACE1 and BACE2. Neuroreport. 2000 Jul 3;12(9):1799-802.

32

32. Fitzjohn SM, Morton RA, Kuenzi F. Age- related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci. 2001 Jul 1;21(13):4691-8.

33

33. Gotz J. Tau and transgenic animal models. Brain Res Brain Res Rev. 2001 Jul;35(3) :266-86. Review.

34

34. Hernandez D, Sugaya K, Qu T, McGowan E, Duff K, McKinney M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precu- rsor protein mutant genes. Neuroreport. 2001 May 25;12(7):1377-84.

35

35. 장우석. Sodium Cyanide로 유도된 신경아세포종 세포주에서 오수유의 항치매효과. 대한한의학회지. 2005;26(3):135-142.

36

36. 황연규. CT99 발현 신경 세포주에서 익기안신탕의 신경보호 및 항치매 효과. 대한한의학방제학회지 2005;13(1):35-48.

37

37. 정정욱, 박창국, 박치상. 산조인(酸棗仁)이 CT105에 의한 신경세포 상해 및 백서의 기억에 미치는 영향. 대한본초학회지. 2005;20(1) :19-33(386)

38

38. 강승준. 조구등이 CT105로 유도된 Alzheimer's disease 병태 모델에 미치는 영향. 대한본초학회지 2003;18(2):157-67.

39

39. 권형수. CT105로 유도된 신경모세포종 세포주에서 세심탕의 항치매 효과. 대한한의학회지 2004;25(2):138-50.

40

40. 송호상. CT105로 유도된 인간 신경아세포종 세포주에서 전매단의 항치매효과. 대한방제학회지 2003;11(2):95-110.

41

41. 강승준. CT105로 유도된 신경모세포종 세포주에서 지미탕의 항치매효과. 대한한방내과학회지. 2004;25(3):482-91.

42

42. 방재선. 가미영신환이 CT105로 유도된 Neuro2A 세포주에서의 항치매 효과. 대한한방내과학회지. 2006;27(3):603-616.

43

43. 황선미. 공진단이 CT105와 β-amyloid로 유도된 Alzheimer's disease 병태모델에 미치는 영향. 동의신경정신과학회지 2004;15(2):103-118.

  • Downloaded
  • Viewed
  • 0KCI Citations
  • 0WOS Citations

Other articles from this issue

Recommanded Articles

상단으로 이동

Journal of Korean Medicine